The genetic determinants of weight gain in people treated for psychosis with all its cardiometabolic consequences, are yet to be fully characterised. It is well established that certain psychotropics are more likely than others to associate with weight gain. However the net contribution of genetic and epigenetic factors to the problem of weight gain is still be determined.
Candidate gene, genome-wide association and linkage studies have provided helpful evidence. However more efforts are needed before risk prediction and personalised medicine can be applied in a clinical setting.
During the session:
- We will review the most recent evidence linking the genome to cardiometabolic trajectory in psychosis
- We will discuss how genetic risk profiling could be applied and the relevance in an everyday clinical setting
- We will discuss how once identified, targeted therapies could be deployed to mitigate the metabolic consequences of antipsychotic treatment
- A survey of service user views on acceptability of genomic profiling will be presented by a patient advocate
This session will help you:
- Appraise the most recent evidence linking the genome to cardiometabolic trajectory in psychosis.
- Enable understanding of the relevance of genetic screening in an everyday clinical setting and to explain how once identified, targeted therapies could be deployed to mitigate the metabolic consequences of antipsychotic treatment.
- Hear of current service user views on acceptability of genomic profiling will be presented by a patient advocate from a recently conducted representative survey of service users.
Chair: Gavin Reynolds, Sheffield Hallam University, United Kingdom
Caroline Dalton, Sheffield Hallam University, United Kingdom
Toby Pillinger, Institute of Psychiatry, London, United Kingdom
Adrian Heald, Salford Royal Hospital, United Kingdom
